Currently, acquired drug resistance in ovarian cancer is mainly considered the result of drug efflux caused by P-glycoprotein, encoded by ATP-binding cassette B1 (ABCB1), which is significantly affected by various lipid compounds especially those residing in their close proximity in the plasma membrane. Here, ABCB1 is linked to ovarian cancer.